Compare MLYS & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLYS | CPRI |
|---|---|---|
| Founded | 2019 | 1981 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2023 | 2011 |
| Metric | MLYS | CPRI |
|---|---|---|
| Price | $29.26 | $18.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $48.67 | $26.62 |
| AVG Volume (30 Days) | 1.7M | ★ 2.6M |
| Earning Date | 05-06-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.43 | ★ 111.40 |
| EPS | N/A | ★ 1.14 |
| Revenue | N/A | ★ $3,474,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.81 |
| P/E Ratio | ★ N/A | $15.70 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.59 | $16.72 |
| 52 Week High | $47.65 | $28.27 |
| Indicator | MLYS | CPRI |
|---|---|---|
| Relative Strength Index (RSI) | 60.61 | 43.03 |
| Support Level | $25.88 | $16.82 |
| Resistance Level | $31.29 | $22.08 |
| Average True Range (ATR) | 1.49 | 0.80 |
| MACD | 0.58 | -0.16 |
| Stochastic Oscillator | 70.30 | 21.41 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.